Medical marijuana has been one of the most effective and versatile treatments for a variety of diseases for decades. Recently, a number of U.S. states added new conditions to their lists of acceptable illnesses to receive such treatments. In Minnesota, sleep apnea patients can now turn to medical marijuana. Michigan also updated its list to include an additional 11 health issues such as autism.
After soliciting public comments as well as reviewing the scientific evidence on hand, the Minnesota Department of Health decided to allow medical marijuana as a treatment for sleep apnea, KSTP reports. This decision was also made after a review panel by citizens was hosted to ensure that the local populace was onboard.
However, not everyone is thrilled about this decision, with some health experts stating that medical marijuana is not as effective in treating the condition as conventional medical treatments. Sleep apnea expert Dr. Jonathan Parker is one such voice to express concern that the development could lead to negative consequences.
Aside from Minnesota, Michigan also decided to update its list of acceptable medical conditions that could receive medical marijuana treatment. These conditions include Parkinson’s disease, chronic pain, and Tourette’s syndrome, the Detroit Free Press reports. The state even threw in autism into the mix for good measure.
In order to make use of medical marijuana, however, patients will need a medical marijuana card. The card must be approved by a doctor and will cost $60.
With these new diseases on the list, the items have now gone up to 22 acceptable ailments. However, even as the state approved the 11 health conditions, it also rejected 11 others. The diseases that were not deemed acceptable to receive medical marijuana treatment include depression, panic attacks, and asthma. That last part might have been the most understandable, however, since it is a respiratory condition.


Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
3 clinical-grade skincare creams you really shouldn’t buy online
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent
France Keeps Top Health Alert as Officials Brace for Another Heatwave
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 



